ANVISA report reduced drug registration times

Brazil’s National Health Surveillance Agency (ANVISA) has reported significant reductions in medicines approval times since Law 12.411 was introduced in March 2017, that facilitates improvements in the evaluation of new registration and post-registration.

An example of the reductions includes the drop in waiting periods from 270 days to 70 days for applications for priority medicines as well as new therapies in the field of rare diseases.

These efficiencies were obtained through changes in work processes such as reprioritising the queue of drug requests and introducing teleworking to the registration process.

For more information, click here.

Tagged with

Published 30. August 2018 in News Brazil